These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20880392)

  • 1. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primate testing of TGN1412: right target, wrong cell.
    Pallardy M; Hünig T
    Br J Pharmacol; 2010 Oct; 161(3):509-11. PubMed ID: 20880391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
    Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
    MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
    Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
    MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
    Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
    PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
    Sandilands GP; Wilson M; Huser C; Jolly L; Sands WA; McSharry C
    Clin Exp Immunol; 2010 Dec; 162(3):516-27. PubMed ID: 20964641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
    Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
    Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
    Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
    Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
    Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
    J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.
    Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1127-1142. PubMed ID: 33033851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    Hünig T
    FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calm after the cytokine storm: lessons from the TGN1412 trial.
    St Clair EW
    J Clin Invest; 2008 Apr; 118(4):1344-7. PubMed ID: 18357347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody C region influences TGN1412-like functional activity in vitro.
    Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
    J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.
    Dudek S; Weißmüller S; Anzaghe M; Miller L; Sterr S; Hoffmann K; Hengel H; Waibler Z
    Eur J Immunol; 2019 Jul; 49(7):1117-1126. PubMed ID: 31002172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway.
    Ndejembi MP; Teijaro JR; Patke DS; Bingaman AW; Chandok MR; Azimzadeh A; Nadler SG; Farber DL
    J Immunol; 2006 Dec; 177(11):7698-706. PubMed ID: 17114440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.